Obsidian Therapeutics announced a strategic collaboration with Celgene for the discovery and development of novel, regulated cell therapies that utilize Obsidian’s Destabilizing Domain, or DD, technology. Specifically, the collaboration is based on Obsidian’s DD technology for the controlled expression of two immunomodulatory factors, IL12 and CD40L, that have the potential to augment the power of adoptive cell therapies but require precise control to optimize their therapeutic benefit. This multi-year collaboration provides Celgene with the exclusive option to in-license worldwide rights for cell therapy candidates that incorporate DD-regulated IL12 or CD40L for the treatment of cancer. The collaboration includes an upfront payment and equity investment by Celgene, and potential future milestone and royalty payments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.